Identification of new prognostic biomarkers for Stage III metastatic melanoma patients.
Accurately predicting disease outcome among patients bearing Stage III metastatic melanoma is complex. However, current advances in personalized medicine call for ever more precise prognostic assessments, as these have a significant impact not only on the design and analysis of clinical trials, but also on therapeutic decision-making.
Melanoma Institute Australia; North Sydney, NSW Australia ; The University of Sydney; Sydney, NSW Australia.
Hojabr
H
Kakavand
Richard A
RA
Scolyer
John F
JF
Thompson
Graham J
GJ
Mann
BRAF; NRAS; expression profile; melanoma; metastasis; mutation; outcome; pathology; prognosis; treatment